行情

CERS

CERS

Cerus Corp
NASDAQ

实时行情|Nasdaq Last Sale

4.530
+0.030
+0.67%
盘后: 4.530 0 0.00% 16:00 04/02 EDT
开盘
4.550
昨收
4.500
最高
4.670
最低
4.360
成交量
214.12万
成交额
--
52周最高
6.64
52周最低
2.710
市值
7.35亿
市盈率(TTM)
-8.8841
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CERS价格均价为8.00,最高价位9.50,最低价为7.00。

EPS

CERS 新闻

更多
  • 高盛警告最糟糕情况下 标普500指数成份股盈利或锐减57%
  • 新浪美股 · 24分钟前
  • 俄罗斯据称为今年20美元的油价做准备 将发行更多债券
  • 新浪美股 · 27分钟前
  • 黄金期货周四收高2.9% 5日来首次收高
  • 新浪美股 · 30分钟前
  • 60%的美国人认为经济"糟糕" 而1月份时67%认为经济"良好"
  • 新浪美股 · 41分钟前

所属板块

医疗设备、用品及经销
+2.96%
医疗设备和用品
+3.40%

热门股票

代码
价格
涨跌幅

CERS 简况

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
展开

微牛提供Cerus Corporation(NASDAQ-CERS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CERS股票新闻,以帮助您做出投资决策。